Condition: Lupus Nephritis · Sponsor: Novartis Pharmaceuticals
The purpose of this up to 6-year extension study is the evaluation of the efficacy and safety 1. after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response \[CRR\] or partial renal response \[PRR\]) on double-blind treatment at the end of the SIRIUS-LN core study, and 2. of open-label ianalumab 300 mg treatment in patients who, at the end of the SIRIUS-LN core study, were either already receiving ianalumab open-label treatment or did not meet CRR/PRR criteria on double-blind treatment at the end of the SIRIUS-LN core study.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| Circuit Clinical | Orchard Park, New York, United States | Recruiting |
| Novartis Investigative Site | Vitória, Espírito Santo, Brazil | Recruiting |
| Novartis Investigative Site | Salvador, Estado de Bahia, Brazil | Recruiting |
| Novartis Investigative Site | Belo Horizonte, Minas Gerais, Brazil | Recruiting |
| Novartis Investigative Site | Santo André, São Paulo, Brazil | Recruiting |
| Novartis Investigative Site | Guangzhou, Guangdong, China | Recruiting |
| Novartis Investigative Site | Shantou, Guangdong, China | Active Not Recruiting |
| Novartis Investigative Site | Shenzhen, Guangdong, China | Recruiting |
| Novartis Investigative Site | Liuzhou, Guangxi, China | Recruiting |
| Novartis Investigative Site | Wuhan, Hubei, China | Recruiting |
| Novartis Investigative Site | Changchun, Jilin, China | Recruiting |
| Novartis Investigative Site | Binzhou, Shandong, China | Recruiting |
+ 29 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06711887